Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094093 | 0.76 | HSP90AA1 (0.35) | HTT | |
| SCHEMBL30848588 | 0.71 | KDM4E (0.33) | CHRM1 | |
| SCHEMBL13086354 | 0.70 | — | — | |
| SCHEMBL14339845 | 0.70 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL8317645 | 0.69 | CYP11B2 (0.39) | — | |
| SCHEMBL13859949 | 0.69 | TSHR (0.35) | HTTCHRM2CHRM1HRH1 | |
| SCHEMBL1577597 | 0.68 | PTGS2 (0.41) | — | |
| SCHEMBL27587040 | 0.67 | PTGS2 (0.40) | — | |
| SCHEMBL7093600 | 0.67 | CYP11B1 (0.41) | HTT | |
| SCHEMBL7095208 | 0.67 | CYP11B1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
| US-8889674-B2 | Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8178553-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20100120838-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-05-13 | — | — | US | disclosed |
| US-7683088-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070265299-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | ABCC4 770/4885PTGS1 1239/4885HTT 1669/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | ABCC4 1557/4885PTGS1 367/4885HTT 3449/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | ABCC4 3332/4885PTGS1 1201/4885HTT 56/4885 |
| US-20100120838-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | ABCC4 2993/4885PTGS1 144/4885HTT 887/4885 |
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | ABCC4 4259/4885PTGS1 4170/4885HTT 303/4885 |
| US-20070265299-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ABCC4 2993/4885PTGS1 144/4885HTT 887/4885 |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | ABCC4 1874/4885PTGS1 3783/4885HTT 1527/4885 |
| US-20110319412-A1 | PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | ABCC4 3083/4885PTGS1 2998/4885HTT 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.